ArticleFish physiology and biochemistry2025
Dietary succinic acid mitigates adverse effects of starch high-starch diet in largemouth bass (Micropterus salmoides) through gut-liver axis modulation.
Article in Fish physiology and biochemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
A 10-week feeding trial was conducted to investigate the effects of succinic acid (SUA) supplementation in high-starch diets (HSD) on growth and enterohepatic health of largemouth bass (Micropterus salmoides; initial weight 11.96 ± 0.71 g). Six isocaloric and isolipidic diets were formulated, comprising a standard diet containing 10% corn starch and 40% fish meal, an HSD with 15% corn starch and 36% fish meal, and HSDs supplemented with 0.5%, 1.0%, 1.5%, and 2.0% SUA. Compared to standard diet, HSD exhibited adverse effects including impaired feed utilization, growth retardation, diminished antioxidant capacity, and immune response, along with metabolic dysregulation and gut microbiota disturbances. Significant linear and quadratic dose-responses were detected for multiple parameters: feed conversion ratio, hepatosomatic index, viscerosomatic index, glycogen content, amylase and protease activities, and hepatic antioxidant status. The 0.5% SUA supplementation group demonstrated enhanced intestinal morphology, upregulated expression of tight junction proteins (ZO-1 and Claudin-4) and antiapoptotic Bcl2, increased abundance of beneficial microbiota and suppressed endoplasmic reticulum stress markers (GRP78, PERK, IRE1, ATF6, eIF2α, and Chopα). Additionally, dietary 0.5% SUA upregulated hepatic anti-inflammatory mediators (Nrf2, TGFβ1, and IL10), glycolytic genes (PK, PFKL2, and GK), β-oxidation-related CPT1, antiapoptotic Bag, and glucose transporter GLUT2, while downregulating proinflammatory TNFα, gluconeogenic enzymes (PEPCK and G6Pase), lipogenic genes (ACC1 and FASN), and proapoptotic Bad. Broken-line regression analysis identified 0.46-0.50% as the optimal SUA inclusion level based on growth parameters. This study demonstrates that appropriate SUA supplementation alleviates HSD-induced oxidative stress, enhances intestinal barrier function, modulates gut microbiota, and maintains metabolic homeostasis, thereby improving starch utilization and growth performance.
Indexed as
Identifiers
40802136What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.